In 2023, global developments highlighted the crucial role of real-world evidence (RWE) in healthcare and drug development. Advancements in AI, regulatory guidance, and transformative legislation shaped these key developments.
The growing need for RWD in healthcare decision-making, especially in evaluating the effectiveness and value of expensive health technologies, poses a challenge that Medlior Health Outcomes Research has effectively addressed for over a decade.
New study raises concerns about impact of IRA drug pricing negotiations on US biopharmaceutical landscape. A new study from Vital Transformation highlighted potential risks in extending the drug pricing provisions of the Inflation Reduction Act (IRA), emphasizing concerns about the impact on patient health, innovative treatments, and the stability of biopharma jobs in the United States.
WHO releases guidelines on AI ethics and governance for large multi-modal models. The World Health Organization (WHO) has released guidance on the ethics and governance of large multi-modal models (LMMs), a form of generative artificial intelligence applied across healthcare domains.
In this interview, we explore the International Consortium for Health Outcomes Measurement (ICHOM), a non-profit established in 2012 to standardize global patient outcomes measurement. Jennifer Bright, the newly appointed president of ICHOM, discusses the challenges and opportunities in collecting meaningful health outcomes data.
Regulators and health technology assessment (HTA) agencies increasingly depend on RWE for decision-making, emphasizing the need for life sciences firms to guarantee the fitness-for-purpose of data used in RWE.
This webinar will discuss designing and selecting data for RWE studies, including external control arm studies, to meet regulatory and HTA requirements.
Microsampling, successful in preclinical and clinical settings, poses lab challenges despite notable collection advancements, highlighting ongoing considerations in the realm of patient-centric sampling.
This webinar delves into analytical insights, tips, and tricks for quantifying patient-centric samples, covering method development, validation, sample handling, and experimental considerations.
Traditional blood sampling through venipuncture for clinical dosage of essential and toxic elements has drawbacks, especially for pediatric patients. Volumetric absorptive microsampling (VAMS®) offers a superior alternative.
This webinar outlines the development, validation, and performance of an ICP-MS/MS method for quantifying diverse toxic and essential elements in blood using VAMS® tips.
